|
gptkbp:instanceOf
|
asset management company
|
|
gptkbp:AUM
|
over $17 billion
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:foundedYear
|
1989
|
|
gptkbp:founder
|
gptkb:Samuel_Isaly
|
|
gptkbp:headquartersLocation
|
gptkb:New_York_City
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
OrbiMed Advisors
|
|
gptkbp:industry
|
healthcare investment
biotechnology investment
life sciences investment
|
|
gptkbp:investedIn
|
private equity
venture capital
public equity
|
|
gptkbp:managingPartner
|
gptkb:Jonathan_Silverstein
Carl L. Gordon
Sven H. Borho
|
|
gptkbp:notableInvestment
|
gptkb:Turning_Point_Therapeutics
gptkb:Moderna
gptkb:Pacific_Biosciences
gptkb:Immunocore
gptkb:CRISPR_Therapeutics
gptkb:Orchard_Therapeutics
gptkb:Replimune
gptkb:Vaxcyte
gptkb:Ascendis_Pharma
gptkb:Kiniksa_Pharmaceuticals
gptkb:Argenx
Tricida
Y-mAbs Therapeutics
|
|
gptkbp:numberOfEmployees
|
over 100
|
|
gptkbp:officeLocation
|
gptkb:Hong_Kong
gptkb:Mumbai
gptkb:San_Francisco
gptkb:Shanghai
Herzliya
|
|
gptkbp:registration
|
SEC-registered investment advisor
|
|
gptkbp:website
|
https://www.orbimed.com/
|
|
gptkbp:bfsParent
|
gptkb:Stephen_Squinto
|
|
gptkbp:bfsLayer
|
7
|